The self-expanding A-Flux device is implanted in the coronary sinus to increase pressure on the venous side of the heart and improve perfusion in smaller vessels.
Landiolol, sold under the brand name Rapiblyk, is only meant to be administered in a hospital setting. It was initially approved for adult patients in 2024.
The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.
The deal includes an upfront payment of $20 million. Stereotaxis could pay up to an additional $25 million if certain regulatory and commercial milestones are met.
Follow-up care after a successful heart transplant can be challenging—both for providers and their patients. Consider, for example, the fact that so many patients who develop complications never actually present with symptoms.
